VastCon is developing a pipeline of drug candidates targeting unique molecular signatures that are drivers of metastases. VastCon is developing a companion diagnostic assay that detects unique molecular signature. The scientific program based on preclinical studies aims at selecting patients most likely to respond to VastCon’s targeted therapies.
|Indication||Preclinical||Phase1/1b||Phase 2||Anticipated Milestone 2019|
|Companion Diagnostic||Pancreatic Cancer||Results from Confirmatory Study from CLIA Labs|
|Small Molecule Inhbitor||Pancreatic Cancer||Preclinical Efficacy Study|
VastCon Inc. is an oncology company focused on developing simple biomarker(s) based tests for cancers and precision therapeutics. VastCon is developing precision therapeutics against unique molecular signatures that drive tumor progression and metastases.